- £139.30m
- £232.88m
- £19.94m
- 34
- 52
- 25
- 27
Annual balance sheet for Life Science Reit, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Cash | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 166 | 45.6 | 14.3 |
| Net Total Accounts Receivable | |||
| Net Total Receivables | 3.16 | 4.13 | 4.25 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 169 | 53.7 | 21 |
| Long Term Investments | |||
| Long Term Notes Receivable | |||
| Other Long Term Assets | |||
| Total Assets | 361 | 448 | 411 |
| Payable / Accrued | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Current Portion of Long Term Debt / Capital Leases | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 10.8 | 50.4 | 14.4 |
| Long Term Debt | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 10.8 | 128 | 127 |
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Total Equity | 351 | 319 | 284 |
| Total Liabilities & Shareholders' Equity | 361 | 448 | 411 |
| Total Common Shares Outstanding |